



Express Mail No. EB 132601945 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Wu, et al.	Confirmation No.:	7123
Serial No.:	10/783,916	Art Unit:	1625
Filed:	February 20, 2004	Examiner:	Davis, Z. N.
For:	Pyridine, Pyrimidine, Quinoline, Quinazoline and Naphthalene Urotensin-II Receptor Antagonists	Attorney Docket No.:	017092-0044-999 (CAM 011104-999013)

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed herewith are the following documents:

1. Petition For Correction of Inventorship Under 37 C.F.R. §1.48(a);
2. Consent of Assignee to Change Inventorship Under 37 C.F.R. §1.48(a) and Statement Under 37 C.F.R. § 3.73(b);
3. Statements from Inventors (3) in Support of Petition for Correction of Inventorship Under 37 C.F.R. §1.48(a);
4. Executed Declaration from Correct Inventors;
5. Issue Fee Transmittal (in duplicate); and
6. Return Postcard.

The Commissioner is hereby authorized to charge fees necessary to Jones Day Deposit Account No. 50-3013 to maintain the pendency of this application.

Respectfully submitted,

Date: June 14, 2007

Dale Rieger (Reg No. 43,045)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939